[The latest research of the molecular biomarker in prostate cancer].

ABSTRACT

The incidence of prostate cancer is rapidly increasing in Japan. Currently, the biomarker of prostate cancer is widely used in clinical is serum PSA only. We need to develop novel molecular markers (biomarkers) that diagnose early prostate cancer so that we can treat appropriately. Recently, the whole genome sequencing analysis has advanced that has made finding of novel molecular markers easier. The best molecular markers identified using personalized genome information will be useful to select appropriate treatment. These therapeutic options for each patient will improve the survival rate. We give an outline about the latest molecular marker basic research with reference to the articles.